Travere Therapeutics reported a total revenue of $59.7 million for the second quarter of 2023, including $57.0 million in net product sales and $2.7 million in licensing and collaboration revenue. The company's cash, cash equivalents, and marketable securities totaled $491.3 million as of June 30, 2023.
Received 417 new patient start forms for FILSPARI in Q2 2023, indicating strong demand for IgAN treatment.
FILSPARI net product sales reached $3.5 million in Q2 2023 and $6.5 million in the first four and a half months post-approval.
Reported positive topline results from Cohort 6 in the Phase 1/2 COMPOSE Study of pegtibatinase in classical homocystinuria (HCU).
Announced an agreement to sell bile acid product portfolio for up to $445 million, strengthening financial foundation.
Travere Therapeutics anticipates a review opinion by the Committee for Medicinal Products for Human Use (CHMP) on the potential approval of the Conditional Marketing Authorization (CMA) application for sparsentan for the treatment of IgAN in Europe around year-end. In late third quarter or early fourth quarter of 2023, the Company expects to report topline results from the two-year confirmatory endpoints in the ongoing Phase 3 PROTECT Study.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance